Healthcare Services

Cancer gene therapy market to reach $8.9B by 2030 at 16.1% CAGR

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Cancer Gene Therapy Market Between 2026 And 2030?

The cancer gene therapy market size has shown rapid expansion in recent years. It is anticipated to increase from $4.21 billion in 2025 to $4.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.4%. The surge observed in the past can be ascribed to advancements in molecular oncology research, the broader scope of clinical trials in gene therapy, rising investment in biopharmaceutical R&D, regulatory clearances for initial gene therapies, and enhanced vector manufacturing capabilities.

The cancer gene therapy market size is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $8.9 billion, exhibiting a compound annual growth rate (CAGR) of 16.1%. This expansion during the projection period stems from various factors, including the escalating demand for tailored cancer treatments, increased investment in cell and gene therapy production, the broadening scope of next-generation viral vectors, a heightened emphasis on combination oncology therapies, and the greater uptake of precision oncology methods. Key trends anticipated in this period encompass the growing advancement of targeted gene therapy platforms, the rising acceptance of CAR-T and TCR therapies, an intensifying focus on optimizing viral vectors, the widening availability of personalized cancer gene treatments, and improved incorporation of biomarker-guided therapy selection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Important Drivers Are Guiding The Cancer Gene Therapy Market Growth?

The rising occurrence of cancer is anticipated to drive the expansion of the cancer gene therapy market in the future. Cancer is defined as a condition marked by the unchecked proliferation of aberrant cells, capable of invading and spreading throughout the body, originating in different tissues and organs, and categorized by its cell or tissue type of origin. The number of cancer cases is escalating because of longer life expectancies, given that the likelihood of developing cancer increases with age. Cancer gene therapy addresses cancer by altering or substituting defective genes to halt the proliferation of cancer cells or to boost the immune system’s capacity to eliminate them. For example, in August 2024, Macmillan Cancer Support, an organization based in the UK, stated that over 3 million individuals in the UK are currently living with cancer. This number is forecasted to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising incidence of cancer is propelling the growth of the cancer gene therapy market.

How Is The Cancer Gene Therapy Market Organized By Segment Classification?

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

What Trends Are Influencing The Evolution Of The Cancer Gene Therapy Market?

Leading companies operating in the cancer gene therapy market are concentrating on developing advanced therapies, such as CAR-T cell therapy, to improve treatment precision, enhance patient outcomes, and target cancer cells more effectively while minimizing damage to healthy tissues. CAR-T therapy is a cutting-edge immunotherapy that involves engineering a patient’s immune cells with special receptors to better detect and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, introduced NexCAR19 (actalycabtagene autoleucel), which is the country’s first indigenously developed CAR-T cell therapy for cancer. Specifically designed to address B-cell lymphomas and leukemias, NexCAR19 functions by reprogramming a patient’s own T cells to identify and eliminate cancer cells. Based on advanced chimeric antigen receptor (CAR) technology, the therapy is manufactured locally, making it more affordable and accessible than imported alternatives. This launch represents a significant milestone for India’s entry into the global cancer gene therapy space, highlighting considerable advancements in domestic innovation and personalized cancer treatment.

Who Are The Industry Participants Involved In The Cancer Gene Therapy Market?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Get The Full Cancer Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Region Leads The Cancer Gene Therapy Market In Overall Market Size?

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company

Farm Equipment Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795